Merck stock climbs on cancer data. Why the drugmaker is more than a one-trick pony.

The company’s partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.
FiercePharma

Merck KGaA confirms late-stage talks with SpringWorks about $3.5B buyout

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. The German drugmaker confirmed (PDF) it is in late-stage talks about buying the rare cancer biopharma for around ...

Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints

Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal ...
Seeking Alpha

Merck KGaA: Diversified Innovation At An Attractive Valuation

Merck KGaA leverages integrated global manufacturing, diversified segments, and innovation to maintain resilience and strategic momentum across pharma, life science, and electronics. MKKGY’s Q4 ...

Exclusive-Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say

By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, Germany’s Merck KGaA and Japan's Ono Pharmaceutical for an experimental ...